How would you treat a fit, newly diagnosed, high-risk multiple myeloma patient with multiple poor risk factors and circulating plasma cells?
In a patient with multiple poor risk features including TP53 mutation, 1q amplification, stage III, and circulating plasma cells, would you consider a more intensive induction therapy? And consolidation with an allogenic transplant?
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Winship Cancer Institute of Emory University
Answered on
So...on most iFISH, we see a deletion of p53, but we don't know about the mutation. Similarly on iFISH we see trisomies and tetrasomies of 1q23, often CKS1B, but not genetic amplification. Finally circulating plasma cells are often missed when less than 5% even at large academic centers, and while t...
Join for free or sign in to see the full answer